Health-related quality of life and inflammatory markers in malignant pleural mesothelioma

Supportive Care in Cancer

Volumn 21, Issue 3, 2013, Pages 697-705

  Kao, Steven C ^a,b,c   Vardy, Janette ^a,c   Harvie, Rozelle ^d   Chatfield, Mark ^e   Van Zandwijk, Nico ^b,c   Clarke, Stephen ^c,d   Pavlakis, Nick ^c,d  

^a SYDNEY CANCER CENTRE   (Australia)

^b Asbestos Diseases Research Institute   (Australia)

^c University of Sydney   (Australia)

^d ROYAL NORTH SHORE HOSPITAL   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Cancer; Health related quality of life; Lung cancer symptom scale; Malignant mesothelioma; Sickness behaviour; Systemic inflammation

Indexed keywords

ANTINEOPLASTIC AGENT; C REACTIVE PROTEIN; CISPLATIN; CYTOKINE; GEMCITABINE; INTERLEUKIN 6; PEMETREXED; THALIDOMIDE; VASCULOTROPIN;

ADULT; AGED; ANOREXIA; ARTICLE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; COUGHING; DYSPNEA; FATIGUE; FEMALE; HUMAN; LUNG CANCER SYMPTOM SCALE; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL; PAIN; PHASE 2 CLINICAL TRIAL; PLEURA MESOTHELIOMA; PLEURECTOMY; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; SELF REPORT; SYMPTOMATOLOGY; VISUAL ANALOG SCALE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATION; LYMPHOCYTES; MALE; MESOTHELIOMA; MIDDLE AGED; NEUTROPHILS; PLEURAL NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; QUALITY OF LIFE; STATISTICS, NONPARAMETRIC; SURVIVAL RATE; THALIDOMIDE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84874029371     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-012-1569-6     Document Type: Article

References (29)

1. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21:2636-2644
2. Hollen PJ, Gralla RJ, Liepa AM, Symanowski J, Rusthoven J (2006) Measuring quality of life in patients with pleural mesothelioma using a modified version of the Lung Cancer Symptom Scale (LCSS): psychometric properties of the LCSS-Meso. Support Care Cancer 14:11-21
3. Nowak AK, Stockler MR, Byrne MJ (2004) Assessing quality of life during chemotherapy for pleural mesothelioma: feasibility, validity, and results of using the european organization for research and treatment of cancer core quality of life questionnaire and lung cancer module. J Clin Oncol 22:3172-3180
4. Gotay CC, Kawamoto CT, Bottomley A, Efficace F (2008) The prognostic significance of patient-reported outcomes in cancer clinical trials. J Clin Oncol 26:1355-1363
5. Quinten C, Coens C, Mauer M, Comte S, Sprangers MAG, Cleeland C, Osoba D, Bjordal K, Bottomley A, Clinical Groups EORTC (2009) Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncol 10:865-871
6. Bottomley A, Coens C, Efficace F, Gaafar R, Manegold C, Burgers S, Vincent M, Legrand C, van Meerbeeck JP, EORTC-NCIC (2007) Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma. J Clin Oncol 25:5770-5776
7. Kelley K, Bluthe R, Dantzer R, Zhou JH, Shen WH, Johnson RW, Broussard SR (2003) Cytokine-induced sickness behavior. Brain Behav Immun 17:S112-S118
8. Dantzer R (2004) Cytokine-induced sickness behaviour: a neuroimmune response to activation of innate immunity. Eur J Pharmacol 500:399-411
9. Myers J (2008) Proinflammatory cytokines and sickness behavior: implications for depression and cancer-related symptoms. Oncol Nurs Forum 35:916-920
10. Seruga B, Zhang H, Bernstein LJ, Tannock IF (2008) Cytokines and their relationship to the symptoms and outcome of cancer. Nat Rev Cancer 8:887-899
11. Robinson BW, Musk AW, Lake RA (2005) Malignant mesothelioma. Lancet 366:397-408
12. Kao SC, Pavlakis N, Harvie R, Vardy JL, Boyer MJ, van Zandwijk N, Clarke SJ (2010) High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clin Cancer Res 16:5805-5813
13. Kao SC, Klebe S, Henderson DW, Reid G, Chatfield M, Armstrong NJ, Yan TD, Vardy J, Clarke S, van Zandwijk N, McCaughan B (2011) Low calretinin expression and high Neutrophil-to-Lymphocyte Ratio are poor prognostic factors in malignant mesothelioma patients undergoing extrapleural pneumonectomy. J Thorac Oncol 6:1923-1929
14. Zahorec R (2001) Ratio of neutrophil to lymphocyte counts - rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek Listy 102:5-14
15. Duffy BK, Gurm HS, Rajagopal V, Gupta R, Ellis SG, Bhatt DL (2006) Usefulness of an elevated neutrophil to lymphocyte ratio in predicting long-term mortality after percutaneous coronary intervention. Am J Cardio 97:993-996
16. Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ (2005) Neutrophil-lymphocyte ratio as a prognsotic factor in colorectal cancer. J Surg Oncol 91:181-184
17. Gomez D, Morris-Stiff G, Toogood GJ, Lodge JP, Prasad KR (2008) Impact of systemic inflammation on outcome following resection for intrahepatic cholangiocarcinoma. J Surg Oncol 97:513-518
18. Sarraf KM, Belcher E, Raevsky E, Nicholson AG, Goldstraw P, Lim E (2009) Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. J Thorac Cardiovasc Surg 137:425-428
19. Chua W, Charles KA, Baracos VE, Clarke SJ (2011) Neutrophil-lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Brit J Cancer 104:1288-1295
20. Kao SC, Harvie R, Paturi F, Taylor R, Davey R, Abraham R, Clarke S, Marx G, Cullen M, Kerestes Z, Pavlakis N (2012) The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin/gemcitabine. Lung Cancer 75:248-254
21. Hollen P, Gralla R, Kris M (1995) An overview of the Lung Cancer Symptom Scale. In: Gralla R, Moinpour C (eds) Assessing quality of life in patients with lung cancer: a guide for clinicians. NCM Publishers, New York, pp 57-59
22. Schroeder MA (1990) Diagnosing and dealing with multicollinearity. West J Nurs Res 12:175-187
23. van Meerbeeck JP, Gaafar R, Manegold C, van Klaveren RJ, van Marck EA, Vincent M, Legrand C, Bottomley A, Debruyne C, Giaccone G, European Organisation for Research and Treatment of Cancer Lung Cancer Group; National Cancer Institute of Canada (2005) Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 23:6881-6889
24. Schubert C, Hong S, Natarajan L, Mills PJ, Dimsdale JE (2007) The association between fatigue and inflammatory marker levels in cancer patients: a quantitative review. Brain Behav Immun 21:413-427
25. Wang X, Shi Q, Williams L, Mao L, Cleeland CS, Komaki RR, Mobley GM, Liao Z (2010) Inflammatory cytokines are associated with the development of symptom burden in patients with NSCLC undergoing concurrent chemoradiation therapy. Brain Behav Immun 24:968-974
26. Pusztai L, Mendoza T, Reuben J, Willey JS, Lara J, Syed A, Fritsche HA, Bruera E, Booser D, Valero V, Arun B, Ibrahim N, Rivera E, Royce M, Cleeland CS, Hortobagyi GN (2004) Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine 25:94-102
27. Jones LW, Eves ND, Mackey JR, Peddle CJ, Haykowsky M, Joy AA, Tankel K, Courneya KS, Reiman T (2008) Systemic inflammation, cardiorespiratory fitness, and quality of life in patients with advanced non-small cell lung cancer. J Thorac Oncol 3:194-195
28. Brown DJF, McMillan DC, Milroy R (2005) The correlation between fatigue, physical function, the systemic inflammatory response, and psychological distress in patients with advanced lung cancer. Cancer 103:377-382
29. Scott HR, McMillan DC, Brown DJF, Forrest LM, McArdle CS, Milroy R (2003) A prospective study of the impact of weight loss and the systemic inflammatory response on quality of life in paitnets with inoperable non-small cell lung cancer. Lung Cancer 40:295-299